Ultragenyx beefs up its take in $186M offering; Idera raises $75M;

@FierceBiotech: Low-profile biotech gets $30M, new CEO and new home for PhIII atrial fib effort. Report | Follow @FierceBiotech

@JohnCFierce: ICYMI: AstraZeneca struggles to spin out anti-infectives division, coming down to the wire. Editor's corner | Follow @JohnCFierce

@DamianFierce: Sprout is resubmitting its "female Viagra" as the FDA faces pressure from advocacy groups. Release | Follow @DamianFierce

> Ultragenyx ($RARE) sold an additional 450,000 shares at $54 a share to the underwriters of its announced offering. The biotech grossed $186 million in the offering. Release

> Idera Pharmaceuticals ($IDRA) raised $75 million in a follow-on offering. Release

Medical Device News

@FierceMedDev: ICYMI: ACT Genomics ropes in $8M for cancer molecular Dx in first private funding round. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Alkermes' multiple sclerosis prodrug looks good in Phase I, has Biogen Idec's Tecfidera in its sights. FierceDrugDelivery article | Follow @VarunSaxena2

@EmilyWFierce: Quick, low-cost tests are becoming the new norm in screening for infectious diseases. Report from the WSJ | Follow @EmilyWFierce

> Hospitals purchasing MRI, CT scanners to take real-time images during surgery. More

> Israeli seed device firm Rainbow Medical raises $25M from Chinese investors. Report

> Swiss developers debut telescopic contact lens triggered by blinking. Story

> Kleiner Perkins-backed Invuity hauls in $20M for surgical lighting tools. Article

Pharma News

@FiercePharma: Aratana confirms hold on USDA-approved dog lymphoma drug. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Activists ready to fight for Ariad CEO's ouster: CNBC. Article | Follow @CarlyHFierce

> Shanghai official linked to GSK bribery sentenced to 19 years in prison. News

> Glaxo's Connelly bows out amid scramble to turn around U.S. business. Article

> Le Figaro: Sanofi will tap Bayer's Brandicourt as CEO this week. Report

Biotech IT News

> Medidata's wearables wish list: Long battery life and water resistance. More

> Microsoft, Cambridge University team up on blood cancer simulation model. Story

> RainDance Technologies opens patent suit against 10X Genomics. Item

> Sanofi-backed virtual trial gets green light in Europe. Report

> Ex-J&J exec turns to crowd to fund brain disorder simulation project. Article

CRO News

> Actavis sells its outsourcing biz to TPG. Item

> Catalent's string of deals pads its pocketbook. More

> Quintiles looks to 2015 with another banner year in the books. Story

> AMRI posts a net quarterly loss in the midst of a realignment. Article

> Charles River rides M&A to a big revenue year. Report

Animal Health News

> Aratana confirms hold on USDA-approved dog lymphoma drug. Item

> Phibro climbs on strong revenue growth, high hopes for new vaccine venture. More

> Trupanion doubles down on quest to make pet insurance more palatable. Story

> Veterinary trade group denounces press reports of alleged conflicts of interest. Article

> Embattled Zoetis beats Q4 expectations, but tempers 2015 forecasts. Report

Biotech Research News

> Singapore research team develops new strategy on inflammation cancer targeting. More

> Science team spotlights a potentially game-changing approach for ovarian cancer. Story

> Investigators advance a new therapy to use against pneumonia, influenza. Article

> Stem cell work points to new approach on fighting obesity. Item

> Alzheimer's group spawns three new R&D centers to advance promising therapies. Report

Pharma Manufacturing News

> Samsung BioLogics to expand new biologics plant. News

> Sun Pharma's revenues squeezed by plant issues. More

> Claris' injectables business is said to be shopped to Pfizer, Amneal. Story

> TPG buys back Aptalis' Pharmatech unit from Actavis. Article

> AMRI plans to close plant in Wales. Report

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.